PMVP
Income statement / Annual
Last year (2023), PMV Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, PMV Pharmaceuticals, Inc.'s net income was -$68.96 M.
See PMV Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.26 M |
$650,000.00 |
$1.28 M |
$318,000.00 |
$388,000.00 |
$338,000.00 |
| Gross Profit |
-$1.26 M |
-$650,000.00 |
-$1.28 M |
-$318,000.00 |
-$388,000.00 |
-$338,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$55.89 M
|
$51.99 M
|
$36.49 M
|
$23.93 M
|
$20.76 M
|
$13.85 M
|
| General & Administrative
Expenses |
$24.25 M
|
$25.05 M
|
$21.80 M
|
$11.01 M
|
$5.88 M
|
$5.04 M
|
| Selling & Marketing
Expenses |
$24.22 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.25 M
|
$25.05 M
|
$21.80 M
|
$11.01 M
|
$5.88 M
|
$5.04 M
|
| Other Expenses |
$0.00 |
$87,000.00 |
$21,000.00 |
-$143,000.00 |
-$8,000.00 |
$16,000.00 |
| Operating Expenses |
$80.13 M |
$77.04 M |
$58.29 M |
$34.94 M |
$26.64 M |
$18.89 M |
| Cost And Expenses |
$80.13 M |
$77.04 M |
$58.29 M |
$34.94 M |
$26.64 M |
$18.89 M |
| Interest Income |
$11.17 M |
$3.63 M |
$449,000.00 |
$651,000.00 |
$1.30 M |
$1.34 M |
| Interest Expense |
$0.00 |
-$4.03 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.26 M
|
$650,000.00
|
$1.28 M
|
$318,000.00
|
$388,000.00
|
$338,000.00
|
| EBITDA |
-$78.88 M
|
-$77.04 M
|
-$58.29 M
|
-$34.94 M
|
-$26.25 M
|
-$18.55 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$11.17 M
|
$3.71 M
|
$470,000.00
|
$508,000.00
|
$1.29 M
|
$16,000.00
|
| Income Before Tax |
-$68.96 M |
-$73.33 M |
-$57.82 M |
-$34.43 M |
-$25.34 M |
-$17.54 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$2,000.00 |
-$9,000.00 |
$23,000.00 |
$6,000.00 |
$8,000.00 |
$3,000.00 |
| Net Income |
-$68.96 M |
-$73.32 M |
-$57.85 M |
-$34.44 M |
-$25.35 M |
-$17.54 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.44 |
-1.61 |
-1.28 |
-0.77 |
-0.59 |
-0.56 |
| EPS Diluted |
-1.44 |
-1.61 |
-1.28 |
-0.77 |
-0.59 |
-0.56 |
| Weighted Average Shares
Out |
$48.01 M
|
$45.59 M
|
$45.14 M
|
$44.78 M
|
$43.00 M
|
$31.23 M
|
| Weighted Average Shares
Out Diluted |
$48.01 M
|
$45.59 M
|
$45.14 M
|
$44.78 M
|
$43.00 M
|
$31.23 M
|
| Link |
|
|
|
|
|
|
